Prophylactic Thyroidectomy in Multiple Endocrine Neoplasia Type 2A
Michael A. Skinner(Imperial College London), Samuel A. Wells(King's College London), Kouros Owzar(Duke University), William G. Dilley(Washington University in St. Louis), Jeffrey Moley(Washington University in St. Louis), Mary K. DeBenedetti(Washington University in St. Louis)
Cited by 380
Related Papers
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
|The Lancet|2009|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group
|Journal of Clinical Oncology|2008|655
Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
|Journal of Clinical Oncology|2010|517